Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Vet Intern Med ; 32(1): 384-393, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29205493

ABSTRACT

BACKGROUND: Prechemotherapy absolute neutrophil count (ANC) cutoffs are arbitrary and vary across institutions and clinicians. Similarly, subjective guidelines are utilized for the administration of prophylactic antibiotics in neutropenic dogs. OBJECTIVES: To evaluate the impact of various ANC cutoffs on chemotherapy administration in dogs with lymphoma treated with CHOP chemotherapy and to determine whether an association between prechemotherapy ANC and subsequent toxicity exists. The secondary objective was to evaluate a currently used ANC cutoff to indicate prescription of prophylactic antibiotics. ANIMALS: Dogs diagnosed with lymphoma treated with CHOP chemotherapy (n = 64). METHODS: Six hundred and fifteen ANCs were stratified into 6 classes. The 3 ANC cutoffs 1.5 × 103 /µL, 2.0 × 103 /µL, and 2.5 × 103 /µL were assessed. The presence of an association between prechemotherapy ANC class and toxicity was determined. Afebrile neutropenic dogs with ANC <1.5 × 103 /µL but above the criteria for prophylactic antibiotics were evaluated. RESULTS: Chemotherapy was not administered in 7% of visits with an ANC cutoff of 1.5 × 103 /µL; chemotherapy would not have been administered in 10% and 16% of visits with an ANC cutoff of 2.0 × 103 /µL or 2.5 × 103 /µL, respectively. There was no association among the 3 lower prechemotherapy ANC classes and toxicity. All dogs with ANC 0.75-1.5 × 103 /µL recovered spontaneously without medical intervention. CONCLUSION AND CLINICAL IMPORTANCE: The number of dose delays was minimized with a prechemotherapy ANC cutoff of 1.5 × 103 /µL, and the prechemotherapy ANC class 1.5-1.99 × 103 /µL was not associated with an increased toxicity. Further investigation of an ANC cutoff near 0.75 × 103 /µL in which to prescribe prophylactic antibiotics is indicated.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Dog Diseases/drug therapy , Lymphoma/veterinary , Neutropenia/veterinary , Animals , Antibiotic Prophylaxis/veterinary , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Blood Cell Count/veterinary , Chemotherapy-Induced Febrile Neutropenia/veterinary , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Cyclophosphamide/therapeutic use , Dogs , Doxorubicin/administration & dosage , Doxorubicin/adverse effects , Doxorubicin/therapeutic use , Female , Lymphoma/drug therapy , Male , Neutropenia/chemically induced , Prednisolone/administration & dosage , Prednisolone/adverse effects , Prednisolone/therapeutic use , Vincristine/administration & dosage , Vincristine/adverse effects , Vincristine/therapeutic use
2.
Vet Comp Oncol ; 12(4): 266-76, 2014 Dec.
Article in English | MEDLINE | ID: mdl-22998454

ABSTRACT

Febrile neutropenia (FN) is an important sequela in veterinary patients receiving chemotherapy. The purpose of this study was to identify factors associated with prolonged hospital stay and outcome in canine patients developing FN secondary to chemotherapy administration. Medical records of 70 dogs treated for FN at the University of Pennsylvania from 1997 to 2010 were retrospectively evaluated. The mean interval between chemotherapy and hospitalization was 7 days. Two-thirds of treated patients had lymphoma. The majority of patients (70%) received vincristine or doxorubicin prior to the development of FN. Tachycardia at admission, complicating medical issues, G-CSF use and decreasing neutrophil count after admission were associated with prolonged hospital stay. Hypotension and G-CSF use were significantly associated with death in-hospital. Mortality was 8.5%. Identification of factors associated with prolonged hospital stay and mortality in patients with FN may enable the development of risk-adapted treatment guidelines to minimize chemotherapy-associated morbidity and mortality.


Subject(s)
Antineoplastic Agents/adverse effects , Chemotherapy-Induced Febrile Neutropenia/veterinary , Dog Diseases/drug therapy , Length of Stay/statistics & numerical data , Neoplasms/veterinary , Animals , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy-Induced Febrile Neutropenia/complications , Chemotherapy-Induced Febrile Neutropenia/mortality , Comorbidity , Dog Diseases/etiology , Dog Diseases/mortality , Dogs , Female , Hospitals, Animal , Logistic Models , Lymphoma/complications , Lymphoma/drug therapy , Lymphoma/veterinary , Male , Neoplasms/classification , Neoplasms/complications , Neoplasms/drug therapy , Pennsylvania/epidemiology , Retrospective Studies , Risk Factors , Schools, Veterinary , Tachycardia/complications , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...